Swiss pharmaceutical giant Roche recently announced the acquisition of Ariosa Diagnostics Inc., a move that will allow Roche to engage in non-invasive prenatal diagnostics. Ariosa is a molecular diagnostics company that develops prenatal testing to assess the risk of Down syndrome and other genetic abnormalities. The financial details of the transaction have not been disclosed. Roche Diagnostics executive Roland Diggelmann said in a statement that the acquisition of Ariosa is another example of Roche's commitment to advance molecular diagnostics. Ariosa's proprietary Harmony Prenatal Test is a blood test that can be performed as early as 10 weeks of pregnancy. This prenatal test is designed to assess the risk of Down syndrome and other genetic abnormalities by evaluating fetal cfDNA found in maternal blood. In particular, the test is capable of assessing the 21, 18, and 13 trisomy, which indicate the presence of an extra chromosome in the fetus that may result in a serious genetic disease risk. The Harmony prenatal testing has accumulated a strong clinical data set and is supported by clinical research in more than 22,000 women of all ages and risk categories, and has passed the US Clinical Laboratory Improvement Amendment (CLIA). Certification. Worldwide, there are more than 200 million pregnant women every year. Prenatal screening for Down syndrome has become a common practice in many countries. The false positive rate of routine screening test feedback is as high as 5%, while the false positive rate of Harmony prenatal testing is less than 0.1%. Circulating cfDNA provides early diagnostic information through simple blood tests that can be applied to a variety of important areas, including maternity, cancer, and organ transplantation. The acquisition is in line with Roche's strategy for personalized medicine and setting new standards for clinical care. In August of this year, Roche's $8.3 billion acquisition of InterMune involved in rare diseases In August of this year, Roche acquired the US biotechnology company InterMune with a 38% premium of 8.3 billion US dollars, which will enable Roche to enter the field of rare diseases and terminal illness treatment. The deal was largely due to Roche's potential for InterMune's Efficient Pulmonary Fibrosis (IPF) drug Esbriet, which was approved by the FDA in October this year. In addition, the FDA also approved the Boehringer Ingelheim (BI) idiopathic pulmonary fibrosis (IPF) drug Ofev (nintedanib). (Related reading: Rare disease IPF market: Roche vs. Boehringer staged - FDA also approved two new IPF drugs) Prior to this, the FDA has not approved any drugs for IPF treatment. Idiopathic pulmonary fibrosis (IPF) is a rare form of lung disease, with 40,000 cases of IPF deaths per year, according to the Association of Pulmonary Fibrosis (CPF) data. Analysts expect that the annual sales of the IPF drug market will exceed 2 billion US dollars. Now the drugs of the two companies are approved for listing at the same time. Which company can win a larger market share will depend on the commercial operation of the two companies. .
B scan:
A scan: A/B Ophthalmic Scanner,A/B Eye Scanner,Ultrasound Ophthalmic A/B Scan,Ophthalmic B-Scan Equipment Guangzhou Sonostar Technologies Co., Limited , https://www.sonoeye.com
Frequency: 10MHz/20MHz (optional) ,Magnetic driven, noiseless
Scanning Mode: Sector Scanning
Magnify:Multi continuous magnification,Real-Time magnification
Resolution: Lateral ≤0.3mm;Vertical≤0.2mm
Geometry position precision: Lateral ≤10%;Vertical≤5%
Depth:60mm
Enhance the part of vitreous body and retina
Gain of probe:30dB-105dB
Scanning Angle:53°
Gray Scale: 256
False Color: Multi colors. OCT
measurement type: multigroup distances, perimeters and areas
Image postprocessing: multiple curves processing, Pseudo-color processing curve
Movies: 100 images movie review, AVI JPG format image output
Frequency:10MHz, with LED
Depth: 40mm
Precision:±0.05 mm
Measurement: Anterior chamber depth, lens thickness, vitreous body length, total length and average
Eye mode: Phakic / Aphakic / Dense / Various IOL
IOL Formula: SRK-II, SRK-T, HOFFER-Q, HOLLADAY,BINKHORST-II, HAIGIS
Stat. Calculation: Average and standard deviation
Store: 10 Scanning results for each eye
Others:
Display Mode :B.B+B.B+A.A
Hint: preset keyword
Case Search:Multi-keywords
Working Platform: Windows XP.VISTA.WINDOWS7
User-defined report template poor credit secured loans